NEW YORK & TOKYO--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that Keio Center for Clinical Research (CCR), one of Japan’s two centers of excellence promoting global clinical research, has chosen to standardize on Medidata Rave^® as its electronic data capture (EDC) and clinical data management (CDM) solution.

Keio CCR was founded in 2006 as an academic research organization within Keio University School of Medicine under the auspices of the Ministry of Health, Labor and Welfare (MHLW) to assume a leading role in the national improvement of clinical trial infrastructure. Designated by the MHLW in 2009 as one of only two centers of excellence to promote global clinical research, Keio CCR plans and supports investigator-initiated, non-NDA clinical trials and observational clinical research, as well as industry-sponsored translational research, registration trials and post-marketing studies.

“Medidata Rave will be key to supporting our strategy of facilitating high-quality clinical research while looking to deliver optimum treatments and improve patient welfare,” said Keio University Center for Clinical Research Professor Yuji Sato M.D., Ph.D.

Keio CCR is upgrading its EDC solution in order to continue to expand, accelerate and improve the quality of its multinational and multicenter clinical studies. Medidata Rave’s scalable, investigator-friendly system, which was originally developed for academic clinical trials, will enable Keio CCR to continue to grow its clinical research capabilities.

Academic research centers, government agencies and other non-profit organizations in all geographies are increasingly selecting Medidata Rave for their clinical trial needs based on Rave’s advanced technology and configurability for any phase, size or therapeutic area trial, as well as Medidata’s customer-centric approach and knowledge transfer program.

“Keio Center for Clinical Research is one of the most well-respected and innovative academic institutions in Japan, and we are excited to help them expand their global clinical program,” said Tarek Sherif, CEO, Medidata Solutions. “Keio’s selection of Medidata Rave is further proof of our ability to understand and deliver solutions that overcome the specific challenges faced by academic research institutions around the world.”

About Keio Center for Clinical Research

Established by Keio University School of Medicine in 2006, Keio Center for Clinical Research(Keio CCR) is a unique academic research organization whose core mission is to facilitate high quality clinical research with the ultimate aim of achieving the highest level of treatment and patient welfare. Toward this goal, we provide comprehensive support to investigators, research subjects, and research sponsors worldwide. For more information, visit www.ccr.med.keio.ac.jp/english.

About Medidata Solutions Worldwide

Medidata Solutions (www.mdsol.com) is a leading global provider of SaaS-based clinical development solutions that enhance the efficiency of customers’ clinical trials. For over 10 years, Medidata has consistently brought next-generation innovation to the life science industry to lower the total cost of clinical development through informed trial planning and management, optimized clinical processes and platform interoperability. Medidata’s advanced solutions address key functions throughout the clinical development process including protocol development (Medidata Designer^®), trial planning and management (Medidata Grants Manager^®, Medidata CRO Contractor^®), user and learning management (iMedidata^™), randomization and trial supply management (Medidata Balance^™), monitoring (Medidata Rave Monitor, Medidata Rave Targeted SDV), Serious Adverse Events capture (Medidata Rave Safety Gateway) and clinical data capture, management and reporting (Medidata Rave^®). Our diverse customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Contacts